CareDx(US:CDNA)2026-02-24 22:30Financial Data and Key Metrics Changes - The company reported Q4 2025 revenue of $108 million, reflecting a 25% year-over-year growth [7][26] - Testing volume increased by 17% year-over-year, with approximately 53,000 tests delivered in Q4 [9][26] - Non-GAAP gross margin was maintained at 69%, with positive adjusted EBITDA of $7 million for the quarter [8][27] - Full year 2025 revenue reached $379.8 million, a 14% increase year-over-year [29][30] - Adjusted EBITDA for the year was $31.7 million, representing a 14% increase over 2024 [31] Business Line Data and Key Metrics Changes - Testing services revenue for Q4 was $78 million, up 23% year-over-year, with kidney testing leading growth [9][26] - Patient and digital solutions revenue for Q4 was $17 million, a 47% increase year-over-year [13][27] - Lab products revenue for Q4 was $13 million, reflecting a 17% year-over-year increase [14][27] Market Data and Key Metrics Changes - Kidney testing growth was supported by increased adoption of surveillance protocols and expanded use of AlloSure Kidney [10][12] - Heart transplantation data showed significant clinical value from HeartCare, with findings published in a major journal [11][12] Company Strategy and Development Direction - The company aims to advance its cell therapy pipeline, referred to as Transplant Plus, and expand into new markets [16][19] - A significant focus on Epic integrations is expected to enhance customer experience and drive volume growth [20][21] - The company is investing in evidence generation through translational research and observational studies to support market access [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for sustained growth and innovation in precision diagnostics [6][39] - The anticipated impact of the draft Local Coverage Determination (LCD) is expected to negatively affect revenue by approximately $15 million [32][33] - The company is optimistic about the potential of AlloHeme in the cell therapy market, with plans for commercialization in early 2027 [18][19] Other Important Information - The company ended Q4 with approximately $200 million in cash equivalents and no debt, providing significant financial flexibility [8][31] - A transition in the CFO role was announced, with Keith Kennedy appointed as the new Chief Operating Officer and Chief Financial Officer [38][39] Q&A Session Summary Question: Volume guidance for the year seems low relative to the exit rate - Management is not assuming an increase in transplant procedural volume and believes it's too early to quantify the impact of Epic Aura [41][42] Question: Sustainability of growth in patient digital solutions - The company expects patient and digital solutions to grow in the range of 8%-12% next year, with margins for software ranging from 60%-70% [43][45] Question: Guidance assumptions and impact of LCD - The guidance includes a $7.5 million revenue reduction due to the LCD, with anticipated revenue per test negatively impacted by $33 [49][53] Question: Opportunities from Epic integration - The company is targeting a three-year goal to increase testing volume, emphasizing the importance of streamlined operations for clean claims [62][63] Question: Commercial readiness for AlloHeme - A broad clinician education effort is planned, along with submission for reimbursement to prepare for the product launch [69][70]